Effectiveness and safety of devil's claw tablets in patients with general rheumatic disorders

Phytotherapy Research

Volumn 21, Issue 12, 2007, Pages 1228-1233

  Warnock, Mary ^a   McBean, Douglas ^a   Suter, Andreas ^b   Tan, Jen ^c   Whittaker, Patricia ^c  

^a QUEEN MARGARET UNIVERSITY   (United Kingdom)

^b Bioforce AG   (Switzerland)

^c Bioforce (UK) Ltd   (United Kingdom)

Author keywords

Devil's Claw; General rheumatic disorders; Harpagophytum; Joint pain

Indexed keywords

ANALGESIC AGENT; HARPAGOPHYTUM PROCUMBENS EXTRACT;

ADULT; AGED; ALGOFUNCTIONAL HAND OSTEOARTHRITIS INDEX; ARTICLE; BACKACHE; BLOOD ANALYSIS; BLOOD CELL COUNT; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELBOW; EVENING DOSAGE; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HAND; HIP; HUMAN; KNEE PAIN; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PAIN; PAIN ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RIGIDITY; SCORING SYSTEM; SELF REPORT; SHOULDER PAIN; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; VITAL SIGN; WESTERN ONTARIO AND MCMASTERS UNIVERSITY OSTEOARTHRITIS INDEX; WRIST;

AGED; BLOOD CELL COUNT; FEMALE; HARPAGOPHYTUM; HUMANS; JOINT DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PLANT EXTRACTS; RHEUMATIC DISEASES;

HARPAGOPHYTUM;

EID: 37849003121     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2288     Document Type: Article

References (23)

1. Baghdikian B, Lanhers MC, Fleurentin J et al. 1997. An analytical study, anti-inflammatory and analgesic effects of Harpagophytum procumbens and Harpagophytum zeyheri. Planta Med 63: 171-176.
2. Baker M. 2000. Modernising the NHS. Patient care (empowerment): the view from a national society. Br Med J 320: 1660-1662.
3. Bellamy N. 2000. WOMAC Osteoarthritis Index User Guide IV. Australia.
4. Burger JFW, Brandt EV, Ferreira D. 1987. Iridoid and phenolic glycosides from Harpagophytum procumbens. Phytochemistry 26: 1453-1457.
5. Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B. 2000. Effectiveness and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine 7: 177-183.
6. Chrubasik S, Zimpfer C, Schutt U, Ziegler R. 1996. Effectiveness of Harpagophytum procumbens in treatment of acute low back pain. Phytomedicine 3: 1-10.
7. Dreiser RL, Maheu E, Guillou GB, Caspard H, Grouin JM. 1995. Validation of an algofunctional index for osteoarthritis of the hand. Rev Rhum Engl Ed 62(6 Suppl 1): 43S-53S.
8. Grahame R, Robinson BV. 1981. Devils's claw (Harpagophytum procumbens): pharmacological and clinical studies. Ann Rheum Dis 40: 632.
9. Grant L, McBean DE, Fyfe L, Warnock AM. 2007. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytother Res 21: 199-209.
10. Hallert E, Husberg M, Skogh T. 2006. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology (Oxford) 45: 325-331.
11. Hootman JM, Helmick CG. 2006. Projections of US prevalence of arthritis and associated activity limitations. Arthr Rheum 54: 226-229.
12. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. 2006. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65: 1175-1183.
13. Laudahn D, Walper A. 2001. Efficacy and tolerance of Harpagophytum extract LI 174 in patients with chronic non-radicular back pain. Phytother Res 15: 621-624.
14. Osiri M, Maetzel A, Tugwell P. 2007. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand. J Rheumatol 34: 57-63.
15. Reginster JY. 2002. The prevalence and burden of arthritis. Rheumatology (Oxford) 41: 3-6.
16. Singer F, Mayrhofer F, Klein G, Hawel R, Kollenz CJ. 2000. Evaluation of the efficacy and dose-response relationship of dexibuprofen (S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index. Int J Clin Pharmacol Ther 38: 15-24.
17. Ware JE, Kosinski M, Keller SD. 1996. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 34: 220-233.
18. Wegener T. 1999. Therapy of degenerative diseases of the musculoskeletal system with South African devil's claw (Harpagophytum procumbens DC). Wien Med Wochenschr 149: 254-257.
19. Wegener T. 2000. Devil's Claw: From African traditional remedy to modern analgesic and anti-inflammatory. HerbalGram 50: 47-54.
20. Wegener T, Lupke NP. 2003. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens dc). Phytother Res 17: 1165-1172.
21. Woolf AD, Akesson K. 2001. Understanding the burden of musculoskeletal conditions. The burden is huge and not reflected in national health priorities. Br Med J 322: 1079-1080.
22. Yelin EH, Callahan LF. 2005. Special article the economic cost and social and psychological impact of musculoskeletal conditions. Arthr Rheum 38: 1351-1362.
23. Yelin EH, Henke CJ, Epstein WV. 1986. Work disability among persons with musculoskeletal conditions. Arthr Rheum 29: 1322-1333.